Evidence map›Paper›PMID 35386179›Full record

ArticleTherapeutics and clinical risk management2022

The Role of D-Dimers in the Initial Evaluation of COVID-19.

Liliana Baroiu, Ana Cristina Lese, Ioana Anca Stefanopol, Alina Iancu, Caterina Dumitru, Alexandru Bogdan Ciubara, Florin Ciprian Bujoreanu, Nicusor Baroiu, Anamaria Ciubara, Alexandru Nechifor and 2 more

Open access · goldAbstract read
In one paragraph

Article in Therapeutics and clinical risk management, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Predicting the severity of COVID-19 using machine learning methods.BMC medical informatics and decision making · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Liliana Baroiu *Clinical Medical Department, Faculty of Medicine and Pharmacy, "Dunărea de Jos" University of Galați, Galati, Romania.ORCID 0000-0002-7602-8435
Ana Cristina Lese"George Enescu" National University of Arts, Faculty of Visual Arts and Design, Iasi, Romania.ORCID 0000-0002-1569-8187
Ioana Anca Stefanopol *Departament of Morphological and Functional Sciences, Faculty of Medicine and Pharmacy, "Dunărea de Jos" University of Galați, Galati, Romania.ORCID 0000-0002-1748-6540
Alina Iancu *Departament of Morphological and Functional Sciences, Faculty of Medicine and Pharmacy, "Dunărea de Jos" University of Galați, Galati, Romania.ORCID 0000-0001-5901-0818
Caterina Dumitru *Multidisciplinary Integrated Center of Dermatological Interface Research Center (MICDIR), "Dunărea de Jos" University of Galați, Galati, Romania.ORCID 0000-0001-8953-6538
Alexandru Bogdan Ciubara *Departament of Morphological and Functional Sciences, Faculty of Medicine and Pharmacy, "Dunărea de Jos" University of Galați, Galati, Romania.ORCID 0000-0003-0740-3702
Florin Ciprian BujoreanuDermatology Department, "Sf. Parascheva" Infectious Diseases Clinical Hospital, Galati, Romania.ORCID 0000-0003-3029-9245
Nicusor Baroiu *Manufacturing Engineering Department, Faculty of Engineering, "Dunărea de Jos" University of Galati, Galati, Romania.ORCID 0000-0002-1334-7025
Anamaria Ciubara *Clinical Medical Department, Faculty of Medicine and Pharmacy, "Dunărea de Jos" University of Galați, Galati, Romania.
Alexandru Nechifor *Clinical Medical Department, Faculty of Medicine and Pharmacy, "Dunărea de Jos" University of Galați, Galati, Romania.
Lucretia Anghel *Clinical Medical Department, Faculty of Medicine and Pharmacy, "Dunărea de Jos" University of Galați, Galati, Romania.ORCID 0000-0002-9477-6760
Alin Laurentiu TatuClinical Medical Department, Faculty of Medicine and Pharmacy, "Dunărea de Jos" University of Galați, Galati, Romania.ORCID 0000-0003-4290-7068
"Dunarea de Jos" University of Galati · ROClinical Emergency Hospital Bucharest · ROGeorge Enescu University of Arts of Iași · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The COVID-19 pandemic was noted for the high degree of contagion and the large number of cases, as well as for the various clinical forms, from asymptomatic towards rapid evolution to death. The hospitals limited care capacity imposed the need to identify some markers of unfavorable evolution. The purpose of our study is to identify the parameters correlated with COVID-19 unfavorable evolution and to draw the profile of the patient at risk of unfavorable evolution. This set of parameters will help the doctor in deciding whether to hospitalize a patient and in choosing the treatment. Patients and Methods: We performed a prospective, observational, actively controlled study on 849 patients with COVID-19, hospitalized in the Second Clinic of "Sf. Cuv. Parascheva" Infectious Diseases Clinical Hospital Galati, Romania, between 1.03.2020-30.11.2020. Results: The parameters statistically significant modified at the admission of the patients with COVID-19 unfavorable evolution were age, oxygen saturation, D-dimers, creatine kinase (CK), troponin, erythrocytes sedimentation rate (ESR), leukocytes, lymphocytes, neutrophils, platelets, hemoglobin (Hb), aspartate transaminase (AST), total and direct bilirubin (TBIL, DBIL), urea, creatinine, serum glucose. Strong correlations were observed between the unfavorable evolution and the admission values of D-dimers, AST, TBIL and between D-dimers and AST, which suggests that D-dimers levels can be considered predictive for the alteration of liver function and for the negative prognosis of the patient. Conclusion: Coagulation disorders and acute respiratory failure are the prevailing causes of death from COVID-19. Together with other parameters that constitute the risk profile for severe COVID-19 evolution, the D-dimers dosing at admission proved to be extremely useful in the management of COVID-19.

Indexed as

aspartate transaminaseCOVID-19D-dimertotal bilirubinunfavorable evolution marker

Identifiers

PMID35386179
PMCPMC8979569
OpenAlexW4220801812

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.